Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05536661
Other study ID # THEA-HYA-GAMERS-2019-01
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date July 4, 2019
Est. completion date July 7, 2019

Study information

Verified date September 2022
Source Laboratorios Thea, Spain
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Clinical, prospective, comparative, controlled, single-blind study, on the signs and symptoms of dry eye before and after 3 days of playing video games with the use of artificial tears (Hyabak) versus no intervention.


Description:

Adult attendees to a Gamers convention will complete questionnairs and undergo an opthalmological evaluation before and after playing for 3 days in a row. Participants will be randomized into 2 groups of equal size: 1. Study group. 2. Control group. The Study group will instill hyaluronic acid 0.15% artificial tears in both eyes 4 times a day during the 3 days of the video game session, while the control group will not instill artificial tears.


Recruitment information / eligibility

Status Completed
Enrollment 56
Est. completion date July 7, 2019
Est. primary completion date July 7, 2019
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - 18 years or older - Participants in videogame convention planning to play video games for a minimum of 6 hours daily for the next 3 days. - Voluntarily accept to participate and sign informed consent form Exclusion Criteria: - Ocular, nasolagrimal or palpebral active condition different from dry eye disease. - History of ocular trauma or infecction in the last 3 months previous to inclusion. - History of refractive surgery. - Visual acuity 0.5 or less in at least 1 eye. - Ocular medication use in the 3 days prior to inclusion. - History of systemic condition asociated to dry eye. - Use of systemic medication known to induce dry eye in the last 30 days. - Known allergy to hyaluronic acid. - Pregnant or lactating women.

Study Design


Intervention

Other:
Preservative free hyaluronic acid artificial tear
Ocular lubricant

Locations

Country Name City State
Spain Dreamhack Convention Valencia

Sponsors (2)

Lead Sponsor Collaborator
Laboratorios Thea, Spain Crossdata

Country where clinical trial is conducted

Spain, 

Outcome

Type Measure Description Time frame Safety issue
Primary Standard Patient Evaluation of Eye Dryness (SPEED) Change in Standard Patient Evaluation of Eye Dryness (SPEED) score between study and control group (range 0-28, with higher scores indicative of dry eye disease symptoms) Between Day 1 and Day 3
Secondary Conjunctival hyperemia measured with McMonnies Chapman scale Change in McMonnies Chapman score (range 0-5, with higher scores indicative of more conjunctival hyperemia) between study and control group Between Day 1 and Day 3
Secondary Tear Breakup Time (TBUT) Change in Tear Breakup Time (TBUT) score (normal values > or equal to 10 seconds) between study and control group Between Day 1 and Day 3
Secondary Conjunctival staining with lisamine green measured with Oxford scale Change in conjunctival oxford staining score (range 0-5 with higher scores indicative of more staining) between study and control group Between Day 1 and Day 3
Secondary Corneal staining with fluorescein measured with Oxford scale Change in corneal oxford staining score (range 0-5 with higher scores indicative of more staining) between study and control group Between Day 1 and Day 3
Secondary Schirmer I tear volume test Change in Schirmer score (normal values equal or higher than 10) between study and control group Between Day 1 and Day 3
Secondary Near convergence measured with a RAF binocular gauge Change in near convergence between study and control group Between Day 1 and Day 3
Secondary Accomodation distance measured with a RAF binocular gauge Change in accomodation distance between study and control group Between Day 1 and Day 3
See also
  Status Clinical Trial Phase
Completed NCT06176651 - Evaluation of Miebo (Perfluorohexyloctane) Eyedrops in Habitual Contact Lens Wearers Phase 4
Completed NCT04091581 - Comparison of Tear Evaporation Rate With Systane Complete in Dry Eye and Non-Dry Eye Phase 4
Active, not recruiting NCT04608942 - Refractory Meibomian Gland Dysfunction and Plasma Jet N/A
Completed NCT03055897 - Tear Film Innovations iLux Safety Study N/A
Completed NCT04658927 - Dextenza With ILUX for Treatment of MGD Phase 4
Not yet recruiting NCT04711642 - Comprehensive Study on Dry Eye and Ocular Surface Disease Prior and After Cataract Surgery Phase 3
Completed NCT03055650 - iLux Treatment for Meibomian Gland Dysfunction (MGD) N/A
Not yet recruiting NCT06158997 - Safety and Effectiveness of EyePeace on Signs and Symptoms of Dry Eye Disease N/A
Completed NCT05331924 - Quality of Life Improvement in Dry Eye Patients After Intense Pulsed Light Therapy Compared to Punctal Plugs N/A
Completed NCT04037969 - Comparison of Tear Evaporation Rate With DAILIES TOTAL1 and Biotrue ONEday N/A